



AB Concentrated Australian Equities Fund Class A

Fund Objective


- The AB Concentrated Australian Equities Fund Class A (the "Fund") aims to achieve returns that exceed the S&P/ASX 300 Accumulation Index after fees over the medium to long term.

Why Consider Investing in This Fund?

- The Fund is designed for investors with high risk tolerances and who want the potential for long-term capital growth and franked dividend income by investing in a concentrated portfolio of approximately 15 to 25 securities listed in Australia.

Fund Structure

Sector Allocation



- Industrials: 20.7%
- Materials: 19.0%
- Financials: 18.7%
- Communication Services: 11.4%
- Healthcare: 10.4%
- Energy: 6.2%
- Consumer Staples: 4.2%
- Consumer Discretionary: 4.1%
- Real Estate: 3.6%
- Cash: 1.0%
- Futures: 0.8%

Numbers may not sum due to rounding.

Key Facts

| | |
|------------------------|----------------|
| Lead Portfolio Manager | Roy Maslen |
| Inception Date | 27 June 2017 |
| Fund Size | A\$551,450,721 |
| APIR | ACM0005AU |
| Minimum Investment | A\$25,000 |
| Entry/Exit Fee | None |
| Buy/Sell Spread | 0.25%/0.25% |
| Management Fee | 0.40% p.a. |
| ICR* | 0.40% p.a. |
| Distribution Frequency | Quarterly |

*Indirect cost ratio (ICR). Financial year to date, annualised.

Fund Performance

| | Gross Fund Returns | Total Returns | Growth Returns | Distribution Returns | Benchmark Returns [†] | Relative Returns |
|------------------|--------------------|---------------|----------------|----------------------|--------------------------------|------------------|
| One Month | -1.13% | -1.16% | -1.16% | 0.00% | 0.98% | -2.14% |
| Three Months | 6.01% | 5.90% | 4.48% | 1.42% | 9.46% | -3.56% |
| FYTD | 5.60% | 5.32% | 3.90% | 1.41% | 9.70% | -4.39% |
| One Year | 7.29% | 6.86% | 2.64% | 4.23% | 10.53% | -3.67% |
| Three Years | 11.26% | 10.76% | 7.38% | 3.38% | 9.09% | 1.67% |
| Five Years | 8.53% | 8.02% | 5.10% | 2.92% | 8.61% | -0.59% |
| Since Inception* | 9.10% | 8.57% | 5.74% | 2.83% | 8.82% | -0.25% |

See Performance Figures disclosures.

* Fund inception: 27 June 2017

† Benchmark: S&P/ASX 300 Accumulation Index

Top 10 Holdings (% Total Net Assets)

| Stock Name | Portfolio | Index |
|------------------------|-----------|-------|
| Westpac Banking | 10.1 | 3.9 |
| Rio Tinto | 9.2 | 2.0 |
| Transurban | 9.1 | 1.8 |
| Telstra | 7.1 | 1.9 |
| CSL | 6.3 | 5.9 |
| Woodside Energy | 6.2 | 2.4 |
| South32 | 4.9 | 0.6 |
| Medibank | 4.4 | 0.4 |
| Computershare | 4.3 | 0.6 |
| Nine Entertainment | 4.3 | 0.1 |
| Total Number of Stocks | 20 | 292 |

Monthly Fact Sheet

Fund Review

- During February, the Fund underperformed the benchmark, the S&P/ASX 300, which was up 0.98% in Australian-dollar terms.

Detractors

- On a sector basis, communication services and materials were the main detractors, while industrials and consumer staples contributed.
- Mining company South32 underperformed, driven initially by softer commodity markets, particularly aluminum falling from US\$2,240 per ton to \$2,132. The company then disappointed the market by approving a new mine with softer-than-hoped investment metrics and cancelling a share buyback.
- A lack of exposure to Wesfarmers detracted from relative results as the conglomerate outperformed the market. Wesfarmers reported 1H earnings with discount department store brands of Kmart and Target materially beating market expectations and provided positive forward-looking commentary.
- Rio Tinto detracted from relative results, while a lack of exposure to BHP contributed. The mining companies underperformed due to weak commodity prices, particularly iron ore, which was down US\$12 per ton in February and \$5 per ton in January.

Contributors

- Integrated services company Downer EDI contributed as its recent result showed strong and stable cash flows.
- Westpac Banking outperformed following a strong quarterly result where it showed better margin outcomes than peers and stable pre-bad debt earnings.

Fund Change Highlights

- During the month, we added to our position in CSL following a period of underperformance triggered by the realisation of negative catalysts that kept us more materially underweight. As the leading player in plasma-derived therapeutics, CSL is a key beneficiary of positive industry trends including strong growth in plasma collection volumes and donor fee cost deflation. While competitive threats are starting to emerge in its core immunoglobulin franchise, increasing penetration in existing indications and growth in new indications should more than offset any near-term headwinds.
- We added shares of Evolution Mining as we rotated our materials and commodities exposure, increasing the Portfolio's allocation to gold as the gold price rallied.
- We trimmed our position in Downer EDI after a run of outperformance.
- We trimmed our position in casino slot machines and online game company Aristocrat Leisure, taking profits as it outperformed the index on a strong start to the year.

Performance Figures

In Australian dollars. Numbers may not sum due to rounding. The total, growth and distribution returns of the Fund are net of fees and costs and do not allow for tax or inflation. Performance is calculated in accordance with the Financial Services Council Standard No. 6, using the relevant end-of-month exit prices, and assumes that income is reinvested and that the investment is held for the full period. The performance figures are historical and past performance is not necessarily an indication of future performance. The information above may change.

AllianceBernstein Investment Management Australia Limited (ABN 58 007 212 606, AFSL 230 683) ("ABIMAL") is the responsible entity of the AllianceBernstein Concentrated Australian Equities Fund (ARSN 102 668 100) ("Fund") and is the issuer of units in the Fund. ABIMAL has appointed AllianceBernstein Australia Limited (ABN 53 095 022 718, AFSL 230 698) ("ABAL") as the investment manager of the Fund. ABAL in turn has delegated a portion of the investment manager function to AllianceBernstein L.P. The Fund's Product Disclosure Statement ("PDS") is available by contacting the client services team at AllianceBernstein Australia Limited at (02) 9255 1299 or at www.alliancebernstein.com.au. Investors should consider the PDS in deciding to acquire, or continue to hold, units in the Fund.

This information is for exclusive use of the wholesale person to whom it is provided and is not to be relied upon by any other person. It is not intended for retail or public use and may not be further distributed without the prior written consent of ABAL.

A Target Market Determination ("TMD") for the Concentrated Australian Equities Fund is available free of charge from our website www.alliancebernstein.com.au. The TMD sets out the class of persons who comprise the target market for the AB Concentrated Australian Equities Fund and the distribution conditions that are applicable, together with a number of other matters which should be considered by retail investors and their advisers.

Information, forecasts and opinions set out in this document are not personal advice and have not been prepared for any recipient's specific investment objectives, financial situation or particular needs. Neither this document nor the information contained in it are intended to take the place of professional advice. Please note that past performance is not indicative of future performance and projections, although based on current information, may not be realised. Information, forecasts and opinions can change without notice, and neither ABIMAL or ABAL guarantees the accuracy of the information at any particular time. Although care has been exercised in compiling the information contained in this report, neither ABIMAL or ABAL warrants that this document is free from errors, inaccuracies or omissions.

This document is released by AllianceBernstein Australia Limited ABN 53 095 022 718, AFSL 230 698

AllianceBernstein Australia Limited Level 32, Aurora Place, 88 Phillip Street, Sydney NSW 2000 T: +61 (0)2 9255 1200

F: +61 (0)2 9247 9910 | Level 49, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000 T: +61 (0)3 8630 2200

F: +61 (0)3 8630 2210 | alliancebernstein.com.au

The [A/B] logo is a registered service mark of AllianceBernstein and AllianceBernstein® is a registered service mark used by permission of the owner, AllianceBernstein L.P. | © 2024 AllianceBernstein L.P.

GEN-FSI-EN-AU-CAE-0224

